



#3 1615

TECH CENTER 1600/2900

JAN 17 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Bechtold-Peters, K. et al ) Art Unit: 1615  
Serial No. : 09/975,418 ) Examiner:  
Confirmation No. : 4479  
Filed : 10/11/2001  
For : Inhalable Powder Containing Tiotropium  
Docket No. : 1/1149

Commissioner for Patents  
Washington, D.C. 20231

January 4, 2002

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56, copies of all the cited references and the International Search Report from the corresponding PCT case citing each reference and indicating the relevance thereof and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,



Philip I. Datlow  
Attorney for Applicant(s)  
Reg. No. 41,482

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road, P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4868

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on January 4, 2002



By: Philip I. Datlow, Reg. No. 41,482